Dexcom (NSDQ:DXCM) said this week that it acquired TypeZero Technologies and its personalized diabetes management solutions. The financial details of the transaction were not disclosed. Dexcom plans to support the first commercial launch of an automated insulin delivery system using TypeZero’s inControl algorithm next year. In March, Dexcom’s latest continuous glucose monitor became the first CGM to […]
typezerotechnologies
Senseonics inks artificial pancreas deal with Roche, TypeZero Technologies
Senseonics (NYSE:SENS) said today that it inked a collaboration with TypeZero Technologies and Roche (OTC:RHHBY) Diabetes Care to develop an automated insulin delivery system. The deal is part of an NIH-funded effort to test artificial pancreas systems. The trial is slated to integrate Senseonic’s Eversense glucose monitor, TypeZero’s inControl AP algorithms and Roche’s Accu-Chek Insight insulin pump. […]
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at Drug Delivery Business’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out […]
Senseonics, TypeZero ink development deal for artificial pancreas
Senseonics (NYSE:SENS) said yesterday that it inked a non-exclusive R&D license agreement with TypeZero Technologies to develop artificial pancreas and decision support systems for its Eversense continuous glucose monitor. The companies plan to integrate glucose readings from the Eversense system with TypeZero’s inControl artificial pancreas algorithms to regulate insulin delivery through a user’s insulin pump. […]
